Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

3 Jul 2014

Abstract excerpt

Active anti-cancer immune responses depend on efficient presentation of tumor antigens and co-stimulatory signals by antigen-presenting cells (APCs). Therapy with autologous natural APCs is costly and time-consuming and results in variable outcomes in clinical trials. Therefore, development of artificial APCs (aAPCs) has attracted significant interest as an alternative. We discuss the characteristics of various...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24998519
DOI: 10.1016/j.tibtech.2014.06.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cellsPMID 24998519Read ↗

Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Semantic proximity Read ↗

The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.Semantic proximity Read ↗

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.Semantic proximity Read ↗

Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated MicrospheresSemantic proximity Read ↗

Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory MoleculesSemantic proximity Read ↗

Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapySemantic proximity Read ↗

Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cellsSemantic proximity Read ↗

Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.Semantic proximity Read ↗

Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer ImmunotherapySemantic proximity Read ↗

Lipid-polymer hybrid nanoparticles utilize B cells and dendritic cells to elicit distinct antigen-specific CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responsesSemantic proximity Read ↗

A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.Semantic proximity Read ↗

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored MembraneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.